Uncluttered Mind, MD
Pre-Clinical Business Framework — Client Evaluation Tool
Evaluation Tool 1 of 2
ASC Buy-In Evaluation
For physicians evaluating ownership in an ambulatory surgery center. Model your buy-in cost, annual return, payback period, and negotiating range before committing to any multiple.
ASC financials
Actual earnings — not PE projections
% of total ASC you are buying into
Typical ASC: 50–70% of EBITDA distributed
Use seller's projection — then stress-test below
Anesthesia, pathology — only if contractually confirmed
Deal structure
Multiple comparison — current EBITDA basis
| Scenario | Multiple | Buy-in cost | Annual distribution | Payback | 5-yr net return | Annual loan pmt | Net after debt | Verdict |
|---|
Your negotiating range
Maximum justifiable price
—
Based on your payback threshold
Fair value (current EBITDA)
—
2.5× current earnings benchmark
PE ask gap
—
Overage vs. your maximum
Ancillary revenue upside
Annual ancillary (your share)
At confirmed ownership %
Adjusted total annual return
—
Distribution + ancillary
Adjusted payback (at PE ask)
—
With ancillary income included
Break-even multiple
—
Highest multiple your threshold supports
Due diligence checklist — before signing
Obtain the operating agreement or shareholder agreement
Confirms entity type, how shares are valued, and whether the seller can sell unilaterally
Verify EBITDA with 3 years of audited financials — not projections
PE projections are not EBITDA. Insist on current performance as the valuation basis
Confirm payer mix and procedure volume trends
Declining commercial volume or rising Medicaid will compress margins post buy-in
Understand distribution policy post-PE acquisition
PE majority ownership often restructures distributions — confirm in writing before signing
Confirm ancillary revenue is contractually available post buy-in
Anesthesia and pathology must be in the operating agreement — verbal assurances are not binding
Assess whether block time is available without owning
Access to the ASC for procedures may not require ownership — evaluate the buy-in as an investment separately from clinical access
